AI eye scan study for retina disease
Part of Eyes & vision clinical trials.
This trial tests whether giving doctors an AI second opinion on retinal scans helps them make better treatment decisions for people with a specific eye disease called nAMD. It's a short, one-time study for eye doctors, not for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an eye doctor (ophthalmologist).
- You must have completed your eye doctor training or be currently in training.
- You must be able to spend about 30 minutes on the study.
- You must agree to the electronic consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new AI-powered camera that takes special pictures of the back of the eye to find signs of wet age-related macular degeneration (AMD) more easily. It compares images from people with wet AMD and healthy volunteers to see if the AI can spot the disease early.
This trial tests a new AI-powered, do-it-yourself screening system for diabetic retinopathy. It may help find early signs of eye disease in people who haven't had an eye exam in the past year.
This trial tests how artificial intelligence can help doctors make better decisions about eye diseases. It may be a good fit if you have an eye condition and can share your medical records and images.
This research tests whether a computer program can help doctors diagnose eye diseases using special scans called OCT. If you have a common retinal condition and have had these scans, you may be eligible to help improve how eye diseases are found.
This trial uses artificial intelligence to analyze eye images and help doctors diagnose eye diseases. It looks at images from routine care to train and test the AI system.
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.